ALLISON SCHULER: Open Payments
NPI 1548924905 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$402 in 12 payments from 10 companies in 2025. Trend: 2023 $30 · 2024 $15 · 2025 $402
Food & beverage: $402
| Company | Payments | Amount |
|---|---|---|
| Exelixis Inc. | 2 | $148 |
| PharmaEssentia USA Corporation | 2 | $51 |
| Janssen Biotech, Inc. | 1 | $37 |
| AstraZeneca Pharmaceuticals LP | 1 | $34 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $29 |
| Lilly USA, LLC | 1 | $28 |
| SOBI, INC | 1 | $22 |
| Astellas Pharma US Inc | 1 | $19 |
| Deciphera Pharmaceuticals Inc. | 1 | $18 |
| Gilead Sciences, Inc. | 1 | $17 |
Products named: CABOMETYX, BESREMI, RYBREVANT, CALQUENCE, Nubeqa, VERZENIO, Doptelet, Vyloy.
Industry payments across MD — which companies pay providers there.
